Ferritin
Code:12006|CPT:82728|LOINC:2276-4
| Includes | Ferritin |
|---|
Analysis details
Methodology
- Electrochemiluminescence immunoassay (ECLIA)
- Immunoturbidimetry
Expected Turnaround Time
1 day
Special Instructions
- Fast for 8 hours before collection; water is allowed.
- If clinically acceptable, stop iron‑containing medications and supplements 72 hours prior to the draw.
- Avoid physical or emotional stress and do not smoke for 30 minutes before collection.
- Use the same assay method for serial measurements; results from different methods are not interchangeable.
- This order is for a single measurement; for longitudinal monitoring, request the designated serial test (480111).
- Assess for high‑dose biotin use; discontinue biotin at least 72 hours before collection.
How to use
Ferritin (serum ferritin; indicator of iron stores) is used to assess whole‑body iron stores and to differentiate iron deficiency anemia from other causes of anemia, including anemia of chronic disease. The test supports evaluation for iron overload, such as hereditary hemochromatosis, in which ferritin and iron saturation are increased. It is also used to track response to therapy in iron deficiency and in conditions associated with iron overload. Because ferritin reflects stored iron, incorporating it with other iron studies enhances diagnostic accuracy. Synonyms such as stored iron and metalloprotein may appear in clinical documentation and refer to the same measurement.
Limitations
Ferritin is the primary intracellular protein for iron storage and is abundant in the liver, bone marrow, spleen, and muscle. Circulating ferritin correlates with iron stores and typically falls early in iron deficiency, often preceding the onset of anemia. Excess iron intake or absorption leads to tissue accumulation and can injure the liver, heart, and pancreas. Ferritin also behaves as an acute‑phase reactant and may be elevated with inflammation, chronic infection, autoimmune disease, liver disease, or malignancy; levels may decline in late pregnancy. Interpretation is strengthened by reviewing complementary iron studies, including serum iron, total iron‑binding capacity, transferrin, and transferrin saturation.
| Unit | ng/mL | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Reference interval |
| |||||||||
| Indications | Abnormal complete blood count suggesting anemia or microcytosis (eg, decreased hemoglobin, hematocrit, or red blood cell count), Clinical suspicion of iron deficiency, Concern for iron overload, including possible hemochromatosis, Workup of anemia in symptomatic patients, Pediatric evaluation when anemia may be affecting learning performance, Monitoring response to treatment for iron deficiency anemia or for disorders with iron overload |
Possible Causes of Abnormal Results
Increased levels
- aging
- alcohol
- autoimmune disease
- chronic infection
- estrogens
- inflammation
- iron supplements
- liver disease
- malignancy
- oral contraceptives
- strenuous exercise
Decreased levels
- biotin (high-dose)
- pregnancy (late)
Specimen Requirements
| Specimen | Serum |
|---|---|
| Container | Gold/Tiger Top (SST, Gel Separator) |
| Volume | 1 mL (min 0.7 mL) |
| Storage Instructions | Room temperature, Refrigerated, Frozen |
References
Centers for Disease Control and Prevention. Iron deficiency−United States, 1999-2000. MMWR. 2002 Oct 11;51(40):897-899. PubMed 12425310.
Centers for Disease Control and Prevention. Recommendations to prevent and control iron deficiency in the United States. MMWR. 1998 Apr 3;47(RR-3):1-36. PubMed 9563847.
Cogswell MS, Looker AC, Pfeiffer CM, et al. Assessment of iron deficiency in US preschool children and nonpregnant females of childbearing age: National Health and Nutrition Examination Survey 2003-2006. Am J Clin Nutr. 2009 May;89(5):1334-1342. PubMed 19357218.
LabCorp internal data.
World Health Organization (WHO). Iron Deficiency Anaemia. Assessment, Prevention, and Control. A guide for programme managers. Geneva: World Health Organization; 2001. (WHO/NHD/01.3). Available from: http://apps.who.int/iris/bitstream/10665/66914/1/WHO_NHD_01.3.pdf?ua=1. Accessed 2008.